The global infectious disease diagnostics market is set to witness a CAGR of ~7% in the next 5 years. Increasing prevalence of infectious diseases, growing threat of emerging infectious diseases, rise in demand for point-of-care testing, technological advancements, rising awareness and initiatives to control infectious diseases spread, and increasing concerns about antimicrobial resistance, are some of the key factors driving the infectious disease diagnostics market.
Infectious-disease diagnostics refers to the procedure of detecting, identifying and characterizing the causative agent of an infectious disease. The diagnosis is based on clinical presentation or more rigorous diagnostic tests, such as culturing of the infectious agent, microscopy, biochemical screens and molecular methods among others. The diagnosis involves methods and equipment used to detect infectious agents like bacteria, viruses, fungi, and parasites in human samples. The diagnosis methods can include traditional techniques like culture and microscopy to advanced molecular methods like polymerase chain reaction (PCR), next-generation sequencing (NGS), and rapid point-of-care (POC) tests. Timely diagnostics helps is preventing disease outbreaks, and track the disease course and response to treatment.
Download a free sample report for in-depth market insights
https://meditechinsights.com/infectious-disease-diagnostics-market/request-sample/
Growing threat of emerging infectious diseases to drive market growth
Emerging infectious diseases are either recently appearing or rapidly spreading infections, that can be caused by previously undetected, unknown, newly recognized, or re-emerging infectious agents. WHO has cautioned that the infectious diseases are emerging at a rapid rate, and since past few decades various new infectious diseases have been discovered, like SARS, MERS, Ebola, chikungunya, avian flu, swine flu, Zika and most recently COVID-19. Outbreaks of such infectious diseases can spread rapidly, causing significant losses to health and livelihood. An effective strategy is to prevent or control their spread at an early stage is early detection and identification of disease or disease-causing agents. Rapid and accurate identification of these agents is essential to prevent outbreaks with the correct control measure. The threat of emerging infectious diseases has highlighted the importance of early detection thus fueling the demand for conventional and advanced diagnostics.
Increasing concerns about antimicrobial resistance to boost market growth
Antimicrobial Resistance (AMR) is a phenomenon that occurs when the infectious agents stop responding to antimicrobial medicines. According to WHO, AMR is one of the top global public health and development threats, and the estimated number of deaths attributed to bacterial AMR were 1.27 million in 2019 globally. Over the years microbes have increasingly developed, acquired antimicrobial resistance to many drugs owing to high selection pressure from increasing use and misuse of antibiotics. Widespread overuse and misuse of antibiotics greatly contributes to antibiotic resistance. Diagnostic tests play an important role here as they help determine when and not antibiotics are an appropriate treatment, thus ensuring right treatment is provided at the right time. This is driving the demand for advanced diagnostics that support better antimicrobial stewardship.
Competitive Landscape Analysis
The global infectious disease diagnostics market is marked by the presence of established and emerging market players such as F. Hoffmann-La Roche Ltd; Abbott; Biomérieux; Thermo Fisher Scientific Inc.; Siemens Healthineers AG; DH Life Sciences, LLC; BD (Becton, Dickinson and Company); Hologic, Inc.; Qiagen; and Revvity; among others. Some of the key strategies adopted by market players include new product development, strategic partnerships and collaborations, and geographic expansion.
Unlock key data with a sample report for competitive analysis:
https://meditechinsights.com/infectious-disease-diagnostics-market/request-sample/
Global Infectious Disease Diagnostics Market Segmentation
This report by Medi-Tech Insights provides the size of the global infectious disease diagnostics market at the regional- and country-level from 2023 to 2030. The report further segments the market based on product and service, testing type, sample type, technology, disease type, and end user.
Market Size & Forecast (2023-2030), By Product and Service, USD Million
- Instruments
- Reagents, Kits and Consumables
- Software and Services
Market Size & Forecast (2023-2030), By Testing Type, USD Million
- Laboratory Testing
- POC Testing
Market Size & Forecast (2023-2030), By Sample Type, USD Million
- Blood, Serum, and Plasma
- Urine
- Others
Market Size & Forecast (2023-2030), By Technology, USD Million
- Immunodiagnostics
- Molecular Diagnostics
- Microbiology
- Others
Market Size & Forecast (2023-2030), By Disease Type, USD Million
- Hepatitis
- Tuberculosis (TB)
- Sexually Transmitted Infections
- Hospital-Acquired Infections (HAIs)
- Influenza
- Others
Market Size & Forecast (2023-2030), By End User, USD Million
- Hospitals & Clinics
- Diagnostic Laboratories
- Academic & Research Institutes
- Others
Market Size & Forecast (2023-2030), By Region, USD Million
- North America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Rest of Asia Pacific
- Latin America
- Middle East & Africa
About Medi-Tech Insights
Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.
Contact:
Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
info@meditechinsights.com
